NCT01012817

ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Study identifier: NCT01012817
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

• Histologically confirmed ovarian epithelial or primary peritoneal cancer
• Refractory to platinum-based therapy OR relapsed < 1 year after receiving a prior platinum-based regimen
• Measurable disease, defined as ≥ 1 lesion whose longest diameter can be accurately measured as ≥ 2.0 cm with conventional techniques or as ≥ 1.0 cm with spiral CT scan
• More than 4 weeks since prior chemotherapy (6 weeks for mitomycin C and nitrosoureas) and recovered
• No history of dose reductions for neutropenia or thrombocytopenia with prior chemotherapy
• No more than 2 prior therapeutic regimens for ovarian epithelial cancer or primary peritoneal cancer

Type of study:

Phase I/II study

Treatment:

Veliparib and topotecan hydrochloride

Study sites:

Arizona
Mayo Clinic Scottsdale
Scottsdale, Arizona, 85259-5499
Contact: Clinical Trials Office - All Mayo Clinic Locations
507-538-7623

Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224
Contact: Clinical Trials Office - All Mayo Clinic Locations
507-538-7623

Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Contact: Clinical Trials Office - All Mayo Clinic Locations
507-538-7623

Web design by Rareheron Web Design